Welcome to this edition of the KRAS Newsletter for December 2022.
Here, we share a collection of articles that highlight the importance of biomarker testing for NSCLC and the ongoing enthusiasm for the potential of KRAS-targeted therapies.
Since the approval of sotorasib for KRAS G12C-mutated NSCLC one year ago, researchers continue to press ahead to extend the benefit of this drug to more patients and to develop therapies for other KRAS mutations.
The lung cancer community is also awaiting an update on adagrasib, which is positioned to become the second KRAS G12C approved drug in the near future.
Take a look below at recent research news in KRAS-positive lung cancer. And don't forget to check out the useful resources for KRAS survivors and their caregivers!
Research News
Public Companies News and Documents via PUBT - Powered by Dow Jones
Amgen Inc. - Biomarker Testing Informs Lung Cancer Treatment: One Patient Tells Her Story
Published Nov 3, 2022
BioPharma Dive
Amgen’s Lumakras launch slows, shifting attention to other drugs
Published Nov 4, 2022
NewsBeezer
Targeted therapies and expanded access to NGS improve lung cancer decision-making
Published Nov 3, 2022
Healio
Sotorasib delays progression of advanced KRAS-mutant non-small cell lung cancer
Published Sep 16, 2022
Vantage
Esmo 2022 – last-minute Kras entry takes centre stage
Published Sep 1, 2022
The Podcast Park [Newswire]
Amgen data at WCLC 2022 highlights potential to deliver transformative medicines for historically difficult-to-treat cancers
Published Aug 8, 2022
Resources for KRAS Survivors & Caregivers
- You have questions? We have answers.
Get the Answers You Need | Navigating KRAS (lungevity.org) - Don’t miss: Top 5 Caregiver Must-Haves
Caregiver Starter Kit: 5 Resources | Navigating KRAS (lungevity.org) - Connect with others dealing with a KRAS diagnosis
Find Your Community | Navigating KRAS (lungevity.org)
If you need further assistance, please email us at support@lungevity.org. Our team is always here to assist you.
